News | May 19, 2026
KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
